Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine
- PMID: 28941623
- DOI: 10.1016/j.vaccine.2017.09.032
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine
Abstract
Background: Menactra® vaccine (MenACWY-D) was licensed in the United States in 2005 for persons 11-55years of age. The aim of this study was to assess the safety of MenACWY-D administered as part of routine clinical care to patients at Kaiser Permanente Northern California (KPNC).
Methods: This was an observational, retrospective study that included all KPNC members who received MenACWY-D during the study period. We monitored all vaccine recipients for non-elective hospitalizations, emergency department visits, and selected outcomes captured in the clinic setting (Bell's palsy, seizures, neuritis, Guillain-Barré syndrome, encephalopathy, encephalitis, epilepsy, transverse myelitis, multiple sclerosis, hypersensitivity reactions, idiopathic thrombocytopenic purpura, diabetes, arthritis, hemolytic anemia, collagen-vascular disease) through 6months after vaccination. Using vaccine recipients as their own controls, we calculated incidence rate ratios (IRRs) of outcomes during the post-vaccination risk interval and compared these with rates during a comparison interval more remote from vaccination. We also compared rates of outcomes in MenACWY-D recipients with those in matched controls who received selected vaccines in the prior year. We reviewed medical records for selected outcomes.
Results: From April 2005 through April 2006, 31,561 KPNC patients (>99% of whom were 11-55years of age) received MenACWY-D. Overall, there were 21 outcomes with significantly elevated IRRs and 44 outcomes with significantly reduced IRRs. Medical record review of outcomes with significantly elevated IRRs did not suggest any relationship with MenACWY-D. Two serious adverse events were considered possibly related to vaccination by the study investigator.
Conclusions: This study did not detect any safety concerns following MenACWY-D and provides reassurance that MenACWY-D administered as part of routine care was not associated with unexpected safety risks. ClinicalTrials.gov Identifier is NCT00254995.
Keywords: Meningitis; Meningococcal infections; Meningococcal vaccines.
Copyright © 2017. Published by Elsevier Ltd.
Similar articles
-
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children.Vaccine. 2018 Apr 12;36(16):2133-2138. doi: 10.1016/j.vaccine.2018.02.107. Epub 2018 Mar 14. Vaccine. 2018. PMID: 29550195
-
Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers.Vaccine. 2016 Jul 29;34(35):4172-4179. doi: 10.1016/j.vaccine.2016.06.062. Epub 2016 Jun 30. Vaccine. 2016. PMID: 27373595 Clinical Trial.
-
Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.Vaccine. 2020 Sep 11;38(40):6291-6298. doi: 10.1016/j.vaccine.2020.07.039. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747215 Free PMC article. Review.
-
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.Vaccine. 2016 Oct 17;34(44):5273-5278. doi: 10.1016/j.vaccine.2016.09.003. Epub 2016 Sep 15. Vaccine. 2016. PMID: 27642132 Clinical Trial.
-
Current safety issues with quadrivalent meningococcal conjugate vaccines.Hum Vaccin Immunother. 2018 May 4;14(5):1175-1178. doi: 10.1080/21645515.2017.1366393. Epub 2017 Nov 8. Hum Vaccin Immunother. 2018. PMID: 28934061 Free PMC article. Review.
Cited by
-
Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.Hum Vaccin Immunother. 2022 Nov 30;18(6):2099142. doi: 10.1080/21645515.2022.2099142. Epub 2022 Aug 10. Hum Vaccin Immunother. 2022. PMID: 35947774 Free PMC article.
-
Bell's palsy following COVID-19 vaccine administration in HIV+ patient.Am J Ophthalmol Case Rep. 2022 Mar;25:101259. doi: 10.1016/j.ajoc.2022.101259. Epub 2022 Jan 20. Am J Ophthalmol Case Rep. 2022. PMID: 35075436 Free PMC article.
-
Bell's palsy and SARS-CoV-2 vaccines.Lancet Infect Dis. 2021 Apr;21(4):450-452. doi: 10.1016/S1473-3099(21)00076-1. Epub 2021 Feb 24. Lancet Infect Dis. 2021. PMID: 33639103 Free PMC article. No abstract available.
-
Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the Republic of Korea, 2014-2019.Infect Dis Ther. 2021 Mar;10(1):399-409. doi: 10.1007/s40121-020-00393-4. Epub 2021 Jan 13. Infect Dis Ther. 2021. PMID: 33439463 Free PMC article.
-
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1. MMWR Recomm Rep. 2020. PMID: 33417592 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous